Breast cancer (Tokyo, Japan)最新文献

{"title":"Correction: Differences in drug efficacy and prognosis between primary and metastatic sites for de novo stage IV breast cancer: an exploratory analysis of a phase III trial, JCOG1017.","authors":"Kiyo Tanaka, Akihiko Shimomura, Makoto Ishitobi, Takashi Yamanaka, Takahiro Tsukioki, Hiroji Iwata, Fumikata Hara, Tomomi Fujisawa, Keita Sasaki, Ryo Sadachi, Riku Kajikawa, Takehiko Sakai, Yasuaki Sagara, Hideo Shigematsu, Yukinori Ozaki, Kazuki Nozawa, Kazuki Sudo, Yoichi Naito, Kaori Terata, Toshiyuki Ishiba, Haruhiko Fukuda, Tadahiko Shien","doi":"10.1007/s12282-026-01874-z","DOIUrl":"10.1007/s12282-026-01874-z","url":null,"abstract":"","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"839-840"},"PeriodicalIF":2.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13283128/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148059210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating the shared genetic architecture and causality of breast cancer and thyroid cancer: genome-wide cross trait analysis and bi-directional Mendelian randomization study.","authors":"Qiaoyu Yang, Haiyun Tang, Yuanjian Fan, Baiying Liu, Yunjian Zhang, Jing Wu","doi":"10.1007/s12282-026-01861-4","DOIUrl":"10.1007/s12282-026-01861-4","url":null,"abstract":"<p><strong>Background: </strong>An epidemiological association between breast cancer (BC) and thyroid cancer (TC) has been found in several observational studies, but whether they share common genetic factors remain unknown. Our research aimed to investigate the shared genetic architecture and potential causal link between BC, including estrogen receptor-positive (ER+) and estrogen receptor-negative (ER-) subtypes, and TC.</p><p><strong>Methods: </strong>Using genome-wide association study (GWAS) summary statistics, we examined the genetic correlation of BC and TC through linkage disequilibrium score regression (LDSC), Heritability Estimation from Summary Statistics (ρ-HESS), and stratified LDSC (S-LDSC). Shared risk single-nucleotide polymorphisms (SNPs) were obtained using cross-trait meta-analysis with Multi-trait Analysis of GWAS (MTAG) and Cross Phenotype Association (CPASSOC). Co-localization analysis was used to identify shared causal genetic variants. Functional annotation and tissue-specific SNP heritability enrichment analysis was used to investigate SNP enrichment at the molecular and tissue levels. Causality was determined by bidirectional Mendelian randomization.</p><p><strong>Results: </strong>A significant, positive global genetic correlation between BC and TC was identified, and was also confirmed in the ER+ subtype. Local genetic correlation analysis identified strong signals in the 2q35 region encompassing rs13387042 (TNP1) and rs966423 (DIRC3). Cross-trait meta-analysis uncovered 23 risk SNPs. Co-localization analysis indicated shared causal variants with high posterior probabilities of shared causality. Gene Ontology enrichment analysis identified significant enrichment in cell cycle G1/S phase transition regulation and Wnt signaling pathway. Bidirectional Mendelian randomization suggested a significant association between BC genetic liability and increased TC risk, particularly in the ER+ subtype.</p><p><strong>Conclusion: </strong>Our study identified a genetic correlation, shared risk genes, and potential causal connection between BC and TC. These findings offered perspectives on the possible mechanisms underlying their comorbidity and the future development of therapeutics.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"862-875"},"PeriodicalIF":2.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147944539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Charcoal localization of metastatic axillary lymphadenopathy in breast cancer patients: concordance with sentinel lymph node biopsy.","authors":"Sepideh Mousavian, Samaneh Sajjadi, Farzaneh Khoroushi, Sahar Ravanshad, Mona Kabiri, Ali Moradi, Mohammad Naser Forghani, Seyed Abbas Tabatabaee Yazdi, Mohsen Mohammadzadeh, Maryam Tavakkoli, Seyed-Ali Alamdaran","doi":"10.1007/s12282-026-01877-w","DOIUrl":"10.1007/s12282-026-01877-w","url":null,"abstract":"<p><strong>Background: </strong>Accurate identification and localization of axillary lymph node involvement in breast cancer before therapeutic interventions, such as neo-adjuvant chemotherapy or surgery, are for optimal disease management. This study evaluates the concordance between charcoal-based localization of axillary lymphadenopathy and sentinel lymph node biopsy.</p><p><strong>Methods: </strong>In this cohort study, 70 patients with breast cancer and up to three metastatic axillary lymph nodes were enrolled at Omid Hospital's radiology department. Nodes were marked with 0.2-0.3 mL charcoal injection under ultrasound guidance. After completion of neoadjuvant chemotherapy, preoperative lymphoscintigraphy was performed. The frequency of positive lymph nodes identified by charcoal staining was compared with the sentinel lymph node findings during surgery.</p><p><strong>Results: </strong>Post-surgical pathology identified charcoal in 89 nodes across 64 patients, yielding a detection rate of 91.4% (95% CI: 85-98%). Among the 64 patients with charcoal- contained nodes, 56 were SLNs containing charcoal, and 8 were non-SLNs, resulting in a concordance rate of 87.5% (95% CI: 79.4%-96%). A chi-square test confirmed a significant association between charcoal-tattooed nodes and SLNs concordance (χ² = 12.3, p < 0.001).</p><p><strong>Conclusions: </strong>This study demonstrated that ultrasound-guided charcoal tattooing of metastatic axillary lymph nodes before Neoadjuvant chemotherapy is a safe, low-cost, and effective technique for localization of limited nodal involvement in breast cancer patients, with high concordance with sentinel lymph node biopsy.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"938-944"},"PeriodicalIF":2.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148152673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in drug efficacy and prognosis between primary and metastatic sites for de novo stage IV breast cancer: an exploratory analysis of a phase III trial, JCOG1017.","authors":"Kiyo Tanaka, Akihiko Shimomura, Makoto Ishitobi, Takashi Yamanaka, Takahiro Tsukioki, Hiroji Iwata, Fumikata Hara, Tomomi Fujisawa, Keita Sasaki, Ryo Sadachi, Riku Kajikawa, Takehiko Sakai, Yasuaki Sagara, Hideo Shigematsu, Yukinori Ozaki, Kazuki Nozawa, Kazuki Sudo, Yoichi Naito, Kaori Terata, Toshiyuki Ishiba, Haruhiko Fukuda, Tadahiko Shien","doi":"10.1007/s12282-026-01846-3","DOIUrl":"10.1007/s12282-026-01846-3","url":null,"abstract":"<p><p>BACKGROUND: Breast cancer is a highly heterogeneous disease, with biological factors like estrogen receptor, progesterone receptor, and HER2 receptor differing between primary and metastatic sites, potentially affecting treatment response. This exploratory analysis aims to differentiate drug efficacy and long-term prognosis between these sites in stage IV breast cancer. METHODS : Patients from JCOG1017, a phase III trial evaluating the role of primary tumor resection, who received primary systemic therapy (PST) were evaluated at three months. In this analysis, treatment response was assessed separately in primary and metastatic sites. Patients were categorized into four groups: discordant I (primary non-PD, metastatic PD), concordant I (both PD), discordant II (primary PD, metastatic non-PD), and concordant II (both non-PD). RESULTS : Among 271 patients, overall discordance proportion of treatment response between primary and metastatic sites was 25.1%. Group distribution was 24.7% (discordant I), 9.6% (concordant I), 0.4% (discordant II), and 65.3% (concordant II). Discordance was more frequent in luminal (28.9%), triple-negative (25.0%), and luminal-HER2 (22.0%) subtypes than in HER2-enriched (11.1%). Survival analysis showed prognostic differences: concordant II, with both sites non-PD, demonstrated the most favorable outcome compared with discordant I (HR 0.556; 95% confidence interval, 0.396–0.782). CONCLUSIONS : One-fourth of patients exhibited discordant responses between primary and metastatic sites in early treatment phases. These discrepancies were associated with survival differences, emphasizing the importance of evaluating both primary and metastatic lesions when assessing efficacy and determining treatment strategies in de novo stage IV breast cancer. </p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"829-838"},"PeriodicalIF":2.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13283142/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147701828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and clinical significance of germline pathogenic variants identified by multigene panel testing in high-risk Japanese patients with breast cancer.","authors":"Miharu Kano, Kanae Taruno, Mayuko Inuzuka, Reiko Makino, Mieko Takeuchi, Misato Suzuki, Kumiko Kida, Junko Takei, Aiko Nagayama, Tetsu Hayashida, Yurie Haruyama, Takayuki Ueno, Chie Watanabe, Yasuyuki Kojima, Rumi Sasai, Mikiko Endo, Yukihide Momozawa, Seigo Nakamura","doi":"10.1007/s12282-026-01863-2","DOIUrl":"10.1007/s12282-026-01863-2","url":null,"abstract":"<p><strong>Background: </strong>In Japan, BRCA genetic testing for the diagnosis of hereditary breast and ovarian cancer is covered by medical insurance. However, other breast cancer (BC) susceptibility genes are rarely examined in these patients, primarily because medical insurance does not cover testing for these genes.</p><p><strong>Methods: </strong>A multigene panel testing (MGPT) was conducted on patients with BC who met the clinical criteria for BRCA genetic testing.</p><p><strong>Results: </strong>Of the 494 patients, 45 germline pathogenic variants (GPVs) were identified (9.11%). The BRCA genetic testing criteria items with GPV detection rates > 10% were as follows: \"diagnosed at age ≤ 45 years,\" \"diagnosed with triple-negative breast cancer (TNBC) at age ≤ 60 years\" and \"≥1 close blood relative within the third degree on the same side of the family with breast, ovarian, or pancreas cancer.\"</p><p><strong>Conclusions: </strong>. MGPT can identify GPVs in genetically high-risk BC patients, including both BRCA1/2 and non-BRCA genes. Thus, MGPT may be an effective approach to support appropriate clinical management for both patients and their relatives.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"887-895"},"PeriodicalIF":2.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13283129/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147937079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative evaluation of treatment recommendations generated by generative AI and breast cancer specialists for advanced and recurrent breast cancer: a multidimensional assessment of evidence interpretation and clinical decision support.","authors":"Maiko Nishida, Rie Tou, Hiroki Kato, Nagisa Hirotani, Sae Kitano, Yuka Okuyama, Chise Matsui, Saya Matsumoto, Akira Watanabe, Erika Iguchi, Mahiro Iizuka-Ohashi, Chikage Kato, Midori Morita, Koichi Sakaguchi, Kengo Yoshii, Yasuto Naoi","doi":"10.1007/s12282-026-01858-z","DOIUrl":"10.1007/s12282-026-01858-z","url":null,"abstract":"<p><strong>Background: </strong>Large language models (LLMs), a form of generative artificial intelligence (AI), are increasingly explored for clinical applications due to their ability to synthesize medical information. In breast cancer care, where therapeutic decision-making is complex because of expanding treatment options, AI-based decision support tools may improve efficiency and consistency. However, their clinical validity and safety remain insufficiently evaluated in real-world settings. The present study aimed to compare the characteristics of treatment recommendations generated by a large language model with those proposed by breast cancer specialists using identical clinical information.</p><p><strong>Methods: </strong>This retrospective observational study included 100 patients with advanced or recurrent breast cancer. Clinical information was provided to ChatGPT using a standardized prompt to generate treatment recommendations. Six board-certified breast cancer specialists independently proposed treatment strategies for the same cases. Recommendations were evaluated using five predefined criteria: 1. Comprehensiveness and appropriateness of literature selection, 2. Accuracy of interpretation of key evidence, 3. Clinical appropriateness and diversity of treatment options, 4. Accuracy of adverse event information, 5. Time required to generate recommendations. Group comparisons were performed using linear mixed-effects models with case and evaluator as random effects.</p><p><strong>Results: </strong>ChatGPT achieved higher scores than specialists across all five evaluation criteria, with the largest difference observed for accuracy of key evidence interpretation. The mean total score was 93.7 for ChatGPT and 44.1 for specialists, and linear mixed-effects model analysis confirmed a significantly higher total score for ChatGPT (p < 0.001). These findings suggest that AI-generated responses tended to provide more comprehensive and structured summaries of available evidence within the predefined evaluation framework.</p><p><strong>Conclusions: </strong>LLMs were able to generate comprehensive and structured treatment recommendations based on the provided clinical information. However, these findings primarily reflect differences in information synthesis under predefined evaluation criteria rather than superiority in real-world clinical decision-making. Given the potential risk of hallucinations, AI should be positioned as an assistive tool to support specialist-led decision-making in breast cancer care.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"841-852"},"PeriodicalIF":2.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147978554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A simple morphometric algorithm based on nuclear atypia features of invasive breast carcinoma: relationship with nuclear grade, Ki-67 level, and hormone receptor status.","authors":"Tomohiro Tsuru, Takanori Watanabe, Keita Kouzu, Youji Yamagishi, Takahiro Einama, Tamio Yamasaki, Hironori Tsujimoto, Yoji Kishi, Hideki Ueno, Hitoshi Tsuda","doi":"10.1007/s12282-026-01870-3","DOIUrl":"10.1007/s12282-026-01870-3","url":null,"abstract":"<p><p>Background With the widespread availability of whole-slide imaging, many studies have utilized digital images of hematoxylin and eosin (H&E)-stained breast cancer tissues and applied convolutional neural networks (CNNs) for pathological diagnosis. However, CNN-based diagnosis is largely a black box and may be limited in quantitative morphological research. In this study, we developed a simple algorithm for morphometric analysis of three nuclear atypia features on H&E-stained whole-slide images to predict nuclear grade, hormone receptor status, and Ki-67 levels in breast cancer.Materials and Methods Using 43,183 H&E-stained nuclear images larger than 20 µm² from 131 invasive ductal breast carcinomas, we calculated the following features of nuclear atypia using a computer vision algorithm: anisonucleosis (variation in nuclear size), inhomogeneous chromatin density, and the average size of prominent nucleoli. Anisonucleosis was quantified as the percentage of nuclei larger than 47 μm². Inhomogeneous chromatin was defined as the percentage of blue-saturated structures with 0.92-fold luminance or less than the average nuclear luminance. Prominent nucleoli were identified based on blue-saturated structures with 0.87-fold luminance or less, circularity greater than 0.65, and size greater than 1.15 μm². Using these values of nuclear atypia features, the thresholds that were the most associated with grade and biomarkers were calculated using receiver operating characteristic curves by Youden index.Results The morphometric algorithm using these thresholds predicted nuclear grade (grade 1 and 3), Ki-67 index ≧ 20%, and hormone receptor negative status with sensitivities of 52.1 to 100% and specificities from 34.3 to 85.3%. Two multivariable logistic regression models combining these three thresholds predicted nuclear grade, Ki-67, and hormone receptor negative with much better accuracy, sensitivities ranging from 57.1 to 91.3%, specificities from 50.9 to 82.2%, and area under curve of 0.70-0.82. The algorithm was applied to an independent set of 42 tumors.Conclusion The present morphological algorithm of nuclear atypia might provide new insights into the computational grading of invasive breast cancer.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"905-918"},"PeriodicalIF":2.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13283171/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148177060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of life in women with breast cancer undergoing chemotherapy: a comparative cross-sectional study of CICC ports and PICC-ports.","authors":"Marco Soldani, Daniele Privitera, Chiara Caradonna, Giuseppe Papagni, Elif Akyüz, Nicolò Capsoni, Chiara Airoldi, Davide Giustivi","doi":"10.1007/s12282-026-01843-6","DOIUrl":"10.1007/s12282-026-01843-6","url":null,"abstract":"<p><p>BACKGROUND: Quality of life (QoL) should be considered when selecting a venous access device for chemotherapy, in addition to clinical indications. This study aimed to describe and compare QoL in women with breast cancer who received a totally implantable vascular device, either a chest port (CICC port) or a peripherally inserted port (PICC-port). METHODS: A single-centre comparative cross-sectional study was conducted including 113 women undergoing neoadjuvant or adjuvant chemotherapy. The QoL was assessed using a questionnaire previously employed in other studies, and a comparative analysis was performed using appropriate parametric or non-parametric tests in accordance with the STROBE guidelines. No multivariable adjustment was performed for baseline differences. RESULTS: Overall satisfaction was high in both groups, with no statistically significant differences in cosmetic concerns or emotional burden. Patients in the CICC port group reported lower pain at insertion (median NRS: 1 vs. 2; p = 0.0099), whereas PICC-port users more frequently reported hygiene difficulties (p = 0.0375). These comparative findings are, however, constrained by relevant baseline differences: women in the PICC-port group were younger and had a lower Body Mass Index, and chemotherapy setting, differed significantly between cohorts. CONCLUSION: Both devices were associated with high patient satisfaction and general acceptance. Minor differences related to insertion pain and hygiene were observed, but their interpretation is limited by unadjusted baseline heterogeneity. Device selection should therefore be grounded primarily in clinical indications and individual patient preferences, while future prospective, multicentre, and adequately adjusted studies are needed to clarify comparative QoL effects. </p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"666-674"},"PeriodicalIF":2.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147483123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fear of diagnosis as a barrier to the screening and diagnosis of breast cancer.","authors":"Anya Mantripragada, Sydney Vaughn, Latha Ganti","doi":"10.1007/s12282-026-01845-4","DOIUrl":"10.1007/s12282-026-01845-4","url":null,"abstract":"<p><p>INTRODUCTION: Breast cancer diagnosis primarily occurs through mammography and biopsy. Treatment options span from surgery to chemotherapy, contingent on the cancer stage. While preventative measures such as lifestyle adjustments like weight management and reduced alcohol intake can reduce cases of breast cancer, challenges persist in accessing timely screening and treatment, especially in low- and middle-income areas of the country. METHODS: This survey engaged 59 US mothers 16 years and older with breast cancer. Administered to ensure distinct responses, it included questions covering family history, personal risk factors, menstrual cycles, pregnancies, barriers to mammograms, and strategies for enhancing healthcare support and awareness. RESULTS: Participant ages were distributed as follows: <18 (1.14%), 18-30 (38.64%), 31-40 (23.86%), 41-50 (21.59%),>50 (14.77%). A family history of ovarian or breast cancer was reported by 41 participants (69%). Identified risk factors included family history (83%), smoking (61%), alcohol consumption (44%), obesity (39%), early menarche (31%), and late menopause (22%). Awareness of recommended breast cancer screening was high, with 48 participants aware (81%). A majority (80%) believed earlier mammograms were warranted. DISCUSSION: Participants underscored the significant genetic component in ovarian or breast cancer and outlined barriers to mammograms such as cost, insurance gaps, and limited awareness of financial aid. They recommended improving healthcare provider awareness, support, and access to mammogram screenings. Enhanced education on breast cancer risks and procedures was also advocated, emphasizing the need for robust support programs to assist patients in navigating their diagnosis effectively. CONCLUSION: The study reveals that in this survey of mothers with breast cancer, women delay mammogram screenings due to financial concerns and fear of diagnosis. Implementing widespread medical aid initiatives can alleviate the stigma of having breast cancer, ultimately increasing screening efforts and reducing the progression and severity of breast cancer in women. </p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"683-692"},"PeriodicalIF":2.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147629717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Three cases of whole breast irradiation for breast cancer in patients with Lymphangioleiomyomatosis (LAM).","authors":"Rumiko Kinoshita, Mitsuchika Hosoda, Fumi Kato, Hirokazu Kimura, Kaoruko Shimizu, Takashi Mori, Kentaro Nishioka, Takayuki Hashimoto, Masato Takahashi, Satoshi Konno, Hidefumi Aoyama","doi":"10.1007/s12282-026-01839-2","DOIUrl":"10.1007/s12282-026-01839-2","url":null,"abstract":"<p><p>Lymphangioleiomyomatosis (LAM) is a rare, low-grade metastatic disease characterized by cystic lung destruction. The existence of increased breast cancer risk among LAM patients, together with the proposed role of estrogen in the onset and progression of LAM, suggests a potential shared pathophysiological mechanism between LAM and breast cancer. We experienced three cases of early-stage breast cancer with LAM. All three cases were treated with breast-conserving surgery followed by radiation therapy and hormone therapy. There were no serious adverse events associated with the radiotherapy, and the patients have progressed without recurrence or metastasis of breast cancer or worsening of LAM in any of the values measured during the follow-up period.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"784-789"},"PeriodicalIF":2.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147346220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}